Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVKen Fisher 2015-06-30 Add$71.71 - $76.45
($74.07)
$ 76.183%Add 5.40%271,515
XLVLeon Cooperman 2015-03-31 Buy 0.42%$67.86 - $74.9
($71.15)
$ 76.187%New holding366,000
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 76.187%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 76.1830%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 76.1897%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 76.18106%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 76.18106%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 76.18118%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 76.18136%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 76.18145%Reduce 93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 76.18161%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 76.18153%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 76.18140%Reduce 43.59%6,600
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 76.18154%New holding11,700
XLVBill Gates 2009-06-30 Sold Out -4.19%$23.76 - $26.53
($25.04)
$ 76.18204%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Neske, Tammy LynnSenior Officer 2015-07-27Buy2,000$6.151138.7view
Fitzgibbon, PierreDirector 2015-07-27Buy3,000$13.38469.36view
Neske, Tammy LynnSenior Officer 2015-07-27Buy5,000$6.071155.02view
Brown, EvanSenior Officer 2015-07-27Buy5,000$61169.67view
Riddell, Clayton H.10% Security Holder 2015-07-27Sell4,000$6.581057.75view
Meade, Harlan DonnleyDirector, Senior Officer 2015-07-27Buy8,000$0.04190350view
Stanyer, Warren WilliamDirector, Senior Officer 2015-07-27Buy1,000$0.1550686.67view
Stanyer, Warren WilliamDirector, Senior Officer 2015-07-27Buy4,000$0.1550686.67view
Dawson, Thomas C.Director 2015-07-27Buy1,800$4.881461.07view
Dawson, Thomas C.Director 2015-07-27Buy2,900$4.91454.69view

Quarterly/Annual Reports about XLV:

    News about XLV:

    Articles On GuruFocus.com
    S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
    Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    Why Sandoz Revenues Were Important for Novartis in 2Q15 Jul 29 2015
    The Huge Spread on the Cigna–Anthem Merger Jul 29 2015
    Cigna Accepts Anthem’s Higher Offer Jul 29 2015
    Why Alcon’s Performance Was Weak in 2Q15 Jul 29 2015
    Why Novartis’s Revenues Declined Marginally Jul 28 2015
    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15 Jul 28 2015
    Leading Economic Index Indicates Steady Growth in the US Jul 28 2015
    Dissecting big pharma's numbers: Pro Jul 28 2015
    Buy market dips and focus on growth: Pro Jul 28 2015
    Investing With A High Probability Of Global Recession Jul 27 2015
    Doctors fight to lower cancer drugs cost Jul 24 2015
    3D printing: Revolutizing prosthetics and sports Jul 24 2015
    Is UnitedHealth Group a Better Partner for Cigna? Jul 22 2015
    The Cigna–Anthem Deal: What’s in It for Cigna? Jul 22 2015
    ETF Analysis: Health Care Select Sector SPDR Jul 22 2015
    Anthem Should Benefit by Acquiring Cigna Jul 21 2015
    Will Anthem Acquire Cigna? Jul 21 2015
    Parsing the Humana-Aetna MAE Clause Jul 21 2015
    The Week Ahead: Damn the Torpedoes .... Jul 18 2015
    UCLA health system hacked Jul 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK